Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The investigators research aim to explores the optimal comprehensive treatment for TNBC and
her2 positive breast cancer by comparing the efficacy of neoadjuvant with that of adjuvant
treatment in improvement of RFS.